Last reviewed 2026-04-20 · How we verify

LAMA

LAMA, marketed by Novartis Pharmaceuticals, is a small molecule with a key composition patent expiring in 2028. Its mechanism of action involves interacting with a specific target in the body to produce a desired effect, positioning it as a targeted therapy in its class. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
• A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
• Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PHASE3)
• Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
• Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (PHASE3)
• Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
• A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils (PHASE2)
• Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.